T. Rowe Price Associates’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

T. Rowe Price Associates’s Portfolio ANAC Stock Details ANAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-300,562	Closed	-$16.1M	–	2595
2016 Q1	$16.1M	Sell	300,562 -4,963	-2%	-$366K	﹤0.01%	1153
2015 Q4	$34.5M	Buy	305,525 +157,225	+106%	+$17.3M	0.01%	902
2015 Q3	$17.5M	Buy	148,300 +8,600	+6%	+$1.12M	﹤0.01%	1137
2015 Q2	$10.8M	Buy	139,700 +52,600	+60%	+$3.45M	﹤0.01%	1326
2015 Q1	$5.04M	Buy	+87,100	New	+$3.7M	﹤0.01%	1471
2013 Q4	–	Sell	-100,000	Closed	-$1.06M	–	2591
2013 Q3	$1.06M	Sell	100,000 -62,187	-38%	-$544K	﹤0.01%	1654
2013 Q2	$907K	Buy	+162,187	New	+$982K	﹤0.01%	1684

Other funds holding ANAC

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

T. Rowe Price Associates's ANAC Position: Q2 2016 in Review

T. Rowe Price Associates sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 300,562 shares — an estimated $16.1M sold.

T. Rowe Price Associates first reported a position in ANAC in Q2 2013 and held it in 7 quarters. The position peaked at $34.5M in Q4 2015. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

T. Rowe Price Associates reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
T. Rowe Price Associates sold 300,562 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $16.1M.
T. Rowe Price Associates first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and held it in 7 quarters.
T. Rowe Price Associates's ANACOR PHARMACEUTICALS INC COM position peaked at $34.5M in Q4 2015.
2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.